Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Erika P. Hamilton, MD, on Treating Breast Cancer With CDK4/6 Inhibitors: Expert Perspective

Posted: Sunday, September 20, 2020

Erika P. Hamilton, MD, of Sarah Cannon Research Institute, discusses the emergence of CDK4/6 inhibitors, how they have transformed the treatment of advanced hormone receptor–positive breast cancers, and what practitioners need to know in order to select the right agent for the right patient.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.